ArticleApplied microbiology and biotechnology2025
Enhancing production and assessing IgE reactivity of dog allergen Can f 6 in Pichia pastoris and Escherichia coli.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systematic optimization ofEngineering microbiology · 2026Review
- Advances in clinical examination techniques for allergic rhinitis: a review from traditional testing to precision diagnosis.Frontiers in allergy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pet allergies are increasingly prevalent in developed nations, significantly affecting humans and strongly linked with asthma and rhinitis. Allergic reactions to cats and dogs affect 15.7% of Americans and 27.2% of Europeans, with sensitization rates to dog allergens reaching 56.0% in Denmark. Despite these concerns, dog ownership remains widespread, with 25% of European and 45.5% of US households owning at least one dog. With sensitization on the rise and current diagnostic and therapeutic approaches predominantly relying on inherently inconsistent allergen extracts derived from natural sources, recombinant allergen production offers a pathway to component-resolved diagnostics, improving specificity and reliability in allergy diagnosis. The present research explored, for the first time, the production of the allergen component glycoprotein Can f 6 in the eukaryotic expression system Pichia pastoris and compared its IgE antigenicity to recombinant Can f 6 (rCan f 6) variants produced in Escherichia coli. Yields were significantly increased by fusing Can f 6 with the maltose binding protein (MBP), resulting in a 1.8-fold increase in production in E. coli and a threefold increase in P. pastoris. Antigenicity analysis showed that N-glycosylation is not critical for folding or IgE recognition of Can f 6, making both systems equally suitable for producing the allergen. Notably, P. pastoris-produced MBP fused protein purified through cation exchange chromatography yielded a lower protein quantity. Still, it exhibited stronger IgE reactivity than the same protein purified using anion exchange chromatography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.